|

Two-cycle induction chemotherapy + immunotherapy Clinical Trials

1 actively recruiting trial

Also known as: 2

Pipeline

Phase 2: 1

Top Sponsors

  • The First Affiliated Hospital of Xiamen University1

Indications

  • Complete Response1
  • Induction Therapy1
  • PD-1 Inhibitor1
  • Nasopharyngeal Neoplasms1
  • Chemotherapy1

Other1 trial

Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.